Keiji AI

Keiji AI develops TrialMind, an agentic AI platform designed to support the full clinical trial lifecycle — from early discovery and trial design through to execution, analysis, and regulatory reporting. The company serves pharmaceutical companies, biotechs, contract research organizations (CROs), and academic medical centers, and reports more than ten enterprise customers with sustained year-over-year growth.

TrialMind is built on over ten years of AI research for drug discovery and development, with findings published in Nature, Nature Biomedical Engineering, Nature Communications, and top AI venues including NeurIPS. The platform incorporates more than ten specialized AI agents and over 100 proprietary MCP tools, drawing on a dataset of more than one million clinical trials to support all six stages of clinical research.

TrialMind Platform Modules

• Discovery: Target identification and mechanism of action analysis.
• Trial Design: Protocol optimization and modeling.
• Real-World Data Analysis: Insights derived from real-world data sources.
• Site Selection: Patient matching and clinical site selection.
• Literature Review: Meta-analysis and evidence synthesis.
• Digital Twin: Prognostic scoring and patient simulation.
• Data Monitoring: On-demand safety monitoring during trial execution.
• Biostatistical Analysis: Statistical modeling and programming.
• Outcome Prediction: Trial success forecasting.

Core Capabilities and Performance

• TrialMind covers all six clinical research stages: Discovery, Planning, Initiation, Execution, Analysis, and Reporting.
• The platform is benchmarked against general-purpose models across multiple tasks, including deep biomedical reasoning, real-world data analysis, literature review, trial design, trial recruitment, drafting, probability of technical and regulatory success (PTRS) prediction, and digital twin simulation.
• On knowledge-intensive biomedical reasoning benchmarks (HLE-Medicine, LabBench-LitQA2, SuperGPQA-Hard), TrialMind reports performance multiples of 1.6× to 12× compared to models such as GPT-5, Claude Sonnet, Biomni, and ToolUniverse.
• Target identification and mechanism of action and pathway reasoning benchmarks show TrialMind performing approximately 1.5× to 1.6× above comparable methods.
• Performance data is sourced from DeepEvidence (arXiv, 2025).

Deployment, Compliance, and Customers

• TrialMind holds four or more enterprise security and compliance certifications, including SOC 2, HIPAA, GxP, and ISO 27001, supporting deployment in regulated healthcare environments.
• The platform is deployed by organizations across top-20 pharmaceutical companies, biotechs, CROs, and academic medical centers.
• The company reports multi-million-dollar annual recurring revenue and 5× year-over-year growth.
• Keiji AI has published more than 100 research publications underpinning the platform's foundational AI methods.

Keiji AI positions TrialMind as a research-grounded, enterprise-validated platform for organizations seeking AI-assisted support across the entire clinical trial process, from early-stage target identification through to regulatory submission and reporting.